Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Encephalomyelitis Overview 6 Therapeutics Development 7 Pipeline Products for Encephalomyelitis - Overview 7 Pipeline Products for Encephalomyelitis - Comparative Analysis 8 Encephalomyelitis - Therapeutics under Development by Companies 9 Encephalomyelitis - Therapeutics under Investigation by Universities/Institutes 10 Encephalomyelitis - Pipeline Products Glance 11 Early Stage Products 11 Encephalomyelitis - Products under Development by Companies 12 Encephalomyelitis - Products under Investigation by Universities/Institutes 13 Encephalomyelitis - Companies Involved in Therapeutics Development 14 Bionure Farma, S.L. 14 Biovista Inc. 15 Effimune SAS 16 InteKrin Therapeutics, Inc. 17 Merck & Co., Inc. 18 Momenta Pharmaceuticals, Inc. 19 Encephalomyelitis - Therapeutics Assessment 20 Assessment by Monotherapy Products 20 Assessment by Target 21 Assessment by Mechanism of Action 23 Assessment by Route of Administration 25 Assessment by Molecule Type 27 Drug Profiles 29 Antibody for Autoimmune Disorders and Inflammation - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 BN-201 - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 FR-104 - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 INT-131 - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 JM-4 - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 PSA-20 - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 SCH-546738 - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 Small Molecule for Chronic Fatigue Syndrome and Myalgic Encephalomyelitis - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 thymulin - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 WEHI-345 - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 Encephalomyelitis - Recent Pipeline Updates 41 Encephalomyelitis - Dormant Projects 44 Appendix 46 Methodology 46 Coverage 46 Secondary Research 46 Primary Research 46 Expert Panel Validation 46 Contact Us 46 Disclaimer 47

List of Tables Number of Products under Development for Encephalomyelitis, H1 2016 7 Number of Products under Development for Encephalomyelitis - Comparative Analysis, H1 2016 8 Number of Products under Development by Companies, H1 2016 9 Number of Products under Investigation by Universities/Institutes, H1 2016 10 Comparative Analysis by Early Stage Development, H1 2016 11 Products under Development by Companies, H1 2016 12 Products under Investigation by Universities/Institutes, H1 2016 13 Encephalomyelitis - Pipeline by Bionure Farma, S.L., H1 2016 14 Encephalomyelitis - Pipeline by Biovista Inc., H1 2016 15 Encephalomyelitis - Pipeline by Effimune SAS, H1 2016 16 Encephalomyelitis - Pipeline by InteKrin Therapeutics, Inc., H1 2016 17 Encephalomyelitis - Pipeline by Merck & Co., Inc., H1 2016 18 Encephalomyelitis - Pipeline by Momenta Pharmaceuticals, Inc., H1 2016 19 Assessment by Monotherapy Products, H1 2016 20 Number of Products by Stage and Target, H1 2016 22 Number of Products by Stage and Mechanism of Action, H1 2016 24 Number of Products by Stage and Route of Administration, H1 2016 26 Number of Products by Stage and Molecule Type, H1 2016 28 Encephalomyelitis Therapeutics - Recent Pipeline Updates, H1 2016 41 Encephalomyelitis - Dormant Projects, H1 2016 44 Encephalomyelitis - Dormant Projects (Contd..1), H1 2016 45 List of Figures Number of Products under Development for Encephalomyelitis, H1 2016 7 Number of Products under Development for Encephalomyelitis - Comparative Analysis, H1 2016 8 Number of Products under Development by Companies, H1 2016 9 Comparative Analysis by Early Stage Products, H1 2016 11 Assessment by Monotherapy Products, H1 2016 20 Number of Products by Targets, H1 2016 21 Number of Products by Stage and Targets, H1 2016 21 Number of Products by Mechanism of Actions, H1 2016 23 Number of Products by Stage and Mechanism of Actions, H1 2016 23 Number of Products by Routes of Administration, H1 2016 25 Number of Products by Stage and Routes of Administration, H1 2016 25 Number of Products by Molecule Types, H1 2016 27 Number of Products by Stage and Molecule Types, H1 2016 27

Bionure Farma, S.L. Biovista Inc. Effimune SAS InteKrin Therapeutics, Inc. Merck & Co., Inc. Momenta Pharmaceuticals, Inc.